Welcome to our dedicated page for Pulmatrix news (Ticker: PULM), a resource for investors and traders seeking the latest updates and insights on Pulmatrix stock.
Pulmatrix, Inc. (PULM) generates news primarily as a clinical-stage biopharmaceutical company focused on inhaled therapeutics built on its patented iSPERSE™ dry powder technology. Company announcements frequently highlight developments in its pipeline of inhaled product candidates for central nervous system and respiratory diseases, including acute migraine, COPD and allergic bronchopulmonary aspergillosis.
News updates often cover clinical milestones for PUR3100, an orally inhaled dihydroergotamine (DHE) candidate for acute migraine, such as publication of Phase 1 results in a peer-reviewed journal and regulatory progress following FDA acceptance of an Investigational New Drug application and a “study may proceed” letter for a Phase 2 study. Pulmatrix also reports on PUR1800, a Narrow Spectrum Kinase Inhibitor for acute exacerbations in chronic obstructive pulmonary disease, including Phase 1b safety and tolerability data, and on PUR1900, its inhaled itraconazole formulation being advanced with partner Cipla outside the United States.
Investors following PULM news will also see regular corporate and strategic updates. These include quarterly and annual financial results, descriptions of cost-saving measures and Pulmatrix’s transition toward a more virtual operating model. The company has issued multiple releases about its proposed merger with Cullgen Inc., detailing stockholder approvals, regulatory steps such as the effectiveness of a registration statement on Form S-4, and conditions to closing, including Nasdaq and China Securities Regulatory Commission approvals. Pulmatrix has also reported entering into a mutual waiver agreement with Cullgen to allow both parties to explore alternative transactions while continuing to pursue the merger.
Additional news items describe licensing and collaboration activity, such as the cross-license agreement and facility transfer with MannKind Corporation involving iSPERSE™ and MannKind’s Cricket® inhalation device. For readers tracking PULM, this news page provides a centralized view of clinical data releases, regulatory filings referenced in press releases, strategic transactions and financial updates that shape the company’s evolution and its inhaled therapeutic programs.
Pulmatrix, Inc. (NASDAQ: PULM) reports its Q2 2020 financial results, highlighting key advancements in its partnerships and product development. The company anticipates a commercial launch of FEND, an OTC nasal hygiene product, in fall 2020, which could generate significant royalty revenues. A Phase 2 clinical study of Pulmazole was halted to pave the way for a new Phase 2b study starting in Q3 2021. As of June 30, 2020, Pulmatrix held $27.3 million in cash, down from $4.8 million in Q2 2019 revenue performance, with an ongoing net loss of $1.2 million in Q2 2020.